Recist versus Choi Criteria Response Assesment in Patients with Advanced Pancreatic Neuroendocrine Tumor (PNET) Treated with Sunitinib Abstract #1247

Introduction: Classically, the response assessment to systemic treatment is based on RECIST. In PNET treated with antiangiogenic targeted therapy as sunitinib there is no good correlation between response rate and progression free survival (PFS). Choi criteria might be an alternative to RECIST to evaluate the effect of sunitinib in patients with advanced PNET
Aim(s): To explore Choi as an appropriate response assessment method in PNET treated with sunitinib.
Materials and methods: 17 patients with advanced PNET treated with sunitinib were evaluated by Computed Tomography (CT) using CHOI and RECIST, every 3 months. According to Choi criteria, partial response (PR) was defined as ≥10% decrease in size or ≥15% decrease in attenuation.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula Jiménez-Fonseca
Keywords: sunitinib, PNET, Choi, RECIST

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2887 CHOI Criteria Are More Accurate Than RECIST in Advanced Pancreatic Neuroendocrine Tumors Treated with Sunitinib: Data from the CRIPNET-GETNE1504 Study
Introduction: Comparative data suggest greater accuracy of Choi vs RECIST in some cancers such as pancreatic neuroendocrine tumors (panNET) treated with antiangiogenic agents.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: PhD Paula Jimenez-Fonseca
#1932 Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study
Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Maria Pilar Solis-Hernandez
Keywords: sunitinib, PNET, choi, recist
#2795 Molecular Correlation of the Activity of Evofosfamide (EVO) in Combination with Sunitinib (SUN) in Pancreatic Neuroendocrine Tumors (pNETs) in the SUNEVO GETNE Trial
Introduction: MEN1, DAXX, ATRX, and PI3K/AKT/mTOR pathway genes are frequently mutated in pNETs. Sunitinib is approved and widely used in the metastatic setting but unfortunately, no validated predictive biomarker has been identified to guide therapy yet. The SUNEVO phase II trial of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumours (GETNE) trial combined the pro-drug of EVO under SUN-induced hypoxic conditions.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Dr. Enrique Grande
#1550 Very Early Response to Sunitinib in VHL Patient with Pancreatic Neuroendocrine Tumor
Introduction: Pancreatic neuroendocrine tumors (pNET) arise in 8-17% of Von Hippel Lindau (VHL) patients and surgery plays a key role for resectable lesions. Alternative medical therapy, such as target therapy (TT), can be used when surgery is unfeasible
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Clinical cases/reports
Presenting Author: MD, PhD Manuela Albertelli
Keywords: VHL therapy
#1760 The Efficacy and Safety of Sunitinib in Patients with Advanced Well Differentiated Pancreatic Neuroendocrine Tumors: Focus on Response Rate
Introduction: In a pivotal phase 3 study (NCT00428597) SU demonstrated a significant increase in progression-free survival (PFS) vs placebo following early study termination.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: MD, PhD Eric Raymond
Authors: Raymond E, Kulke M H, Qin S, Yu X, ...
Keywords: pNET, survival, sunitinib